Beam Announces Agreement for Lilly to Acquire Opt-In Rights to Verve Therapeutics’ Base-Editing Programs for Cardiovascular Disease

Boston – October 31, 2023 – Cooley advised Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, on its agreement with Eli Lilly and Company for Lilly to acquire certain rights under Beam’s amended collaboration and license agreement with Verve Therapeutics – including Beam’s opt-in rights to co-develop and co-commercialize Verve’s base-editing programs for cardiovascular disease. Lawyers Ken Krisko and Christophe Beauduin led the Cooley team advising Beam.

Under the terms of the agreement, Beam will receive $200 million in combined upfront payment and $50 million in equity investment, along with up to $350 million in potential future development-stage payments upon completion of certain clinical, regulatory and alliance events – for a total of up to $600 million in potential total deal consideration.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has more than 1,300 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of nearly 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.